PUBLISHER: Polaris Market Research | PRODUCT CODE: 1478704
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1478704
The global lipid nanoparticle raw materials market size is expected to reach USD 333.85 million by 2032, according to a new study by Polaris Market Research. The report "Lipid Nanoparticle Raw Materials Market Share, Size, Trends, Industry Analysis Report, By Product (Ionizable lipids, Reagents, Other raw materials); By Disease Indication; By Application; By End-use; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The rising demand for the lipid nanoparticle raw materials is highly attributable to the increasing focus on vaccination development. The worldwide population is witnessing a significant surge in chronic health issues, specifically cancer and blood diseases. This is enforcing healthcare researchers to formulate effective diagnosis and treatment procedures in the marketplace, which will significantly facilitate the need for lipid nanoparticle raw materials. For instance, in October 2023, the researchers at the Institute for Biomedical Science announced the development of an oral liquid nanoparticle drug for colitis-associated cancer.
The increasing development of new research institutes is optimally influencing the global lipid nanoparticle raw material market. For instance, in September 2023, Centre for Process Innovation introduced the Center of Excellence RNA in the UK, aiming to produce lipid nanoparticles and RNA for clinical trials. Additionally, the rising investments and grants by the government to fuel scientific developments, specifically to address the problem of inadequate vaccines, will further fuel the production of lipid nanoparticles in the long run. For instance, in September 2023, the RNA Centre of Excellence received funding of GBP 26 million to assist companies in the production and development activities of RNA.
Furthermore, the ongoing product launches are supporting advancements in the development of lipid nanoparticles for the manufacturing of vaccines, cell and gene therapies. For instance, in April 2024, Cayman Chemicals introduced the LipidLaunch research tools that have the potential to discover lipid nanoparticles. The growing research innovations unravel the true potential of the lipid nanoparticles, which will likely drive market growth during the study period. For instance, a 2024 study published in Nature Communication developed the targeted lung carrier system with the use of nanoparticles.
Additionally, the rising efforts taken by the researchers to increase the production capacity of lipid nanoparticles are likely to drive the growth of the lipid nanoparticle raw material market. For instance, in August 2023, researchers unveiled the launch of a new platform that enables a higher rate of production of lipid nanoparticle vaccines (SARS-CoV-2 mRNA).
Kits segment is anticipated to witness the highest growth due to its affordability and flexibility in research activities.
Infectious disease segment accounted for the largest market share owing to the increasing number of health issues due to infections.
Therapeutics segment is projected to experience a larger revenue share due to the growing development of therapies.
APAC is projected to register the fastest growth during the forecast period, attributable to the increasing blood cancer rate in the region.
The global players include Avanti Polar Lipids, Biopharma PEG Scientific Inc., BroadPharm, CordenPharma International, Creative Biolabs, & Echelon Biosciences.
Polaris Market Research has segmented the lipid nanoparticle raw materials market report based on product, disease indication, application, end-use, and region: